FATE vs. IFRX
FATE (Fate Therapeutics, Inc.) and IFRX (InflaRx N.V.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, FATE returned -49.07%/yr vs -6.05%/yr for IFRX. At a 0.25 correlation, their price movements are largely independent.
Performance
FATE vs. IFRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FATE achieves a 215.49% return, which is significantly higher than IFRX's 102.97% return.
FATE
- 1D
- -0.32%
- 1M
- 50.49%
- 6M
- 195.24%
- YTD
- 215.49%
- 1Y
- 169.57%
- 3Y*
- -13.92%
- 5Y*
- -49.07%
- 10Y*
- 5.95%
IFRX
- 1D
- -0.49%
- 1M
- 28.12%
- 6M
- 97.12%
- YTD
- 102.97%
- 1Y
- 132.93%
- 3Y*
- -21.14%
- 5Y*
- -6.05%
- 10Y*
- —
FATE vs. IFRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
FATE Fate Therapeutics, Inc. | 215.49% | -40.45% | -55.88% | -62.93% | -82.76% | -35.65% | 364.64% | 52.53% | 109.98% | 23.94% |
IFRX InflaRx N.V. | 102.97% | -59.11% | 51.53% | -47.42% | -34.87% | -5.37% | 27.02% | -89.11% | 73.60% | 37.92% |
Correlation
The correlation between FATE and IFRX is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Nov 8, 2017 | 0.25 |
Fundamentals
FATE:
$361.33M
IFRX:
$148.08M
FATE:
-$1.09
IFRX:
-€0.60
FATE:
58.54
IFRX:
4.41K
FATE:
2.07
IFRX:
3.51
FATE:
$6.32M
IFRX:
€28.17K
FATE:
-$7.88M
IFRX:
-€7.43M
FATE:
-$135.03M
IFRX:
-€47.19M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FATE vs. IFRX — Risk / Return Rank
FATE
IFRX
FATE vs. IFRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Fate Therapeutics, Inc. (FATE) and InflaRx N.V. (IFRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FATE | IFRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.53 | ||
| Sortino ratioReturn per unit of downside risk | +0.28 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.26 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 4.05 | 2.46 | +1.59 |
| Martin ratioReturn relative to average drawdown | 6.87 | 4.14 | +2.74 |
Loading charts...
Drawdowns
FATE vs. IFRX - Drawdown Comparison
The maximum FATE drawdown since its inception was -99.42%, roughly equal to the maximum IFRX drawdown of -98.58%. Use the drawdown chart below to compare losses from any high point for FATE and IFRX.
Loading charts...
Drawdown Indicators
| FATE | IFRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.42% | -98.58% | -0.84% |
Max Drawdown (1Y)Largest decline over 1 year | -41.58% | -52.83% | +11.25% |
Max Drawdown (3Y)Largest decline over 3 years | -91.86% | -82.69% | -9.17% |
Max Drawdown (5Y)Largest decline over 5 years | -99.29% | -88.02% | -11.27% |
Max Drawdown (10Y)Largest decline over 10 years | -99.42% | — | — |
Current DrawdownCurrent decline from peak | -97.36% | -96.03% | -1.33% |
Average DrawdownAverage peak-to-trough decline | -58.78% | -80.33% | +21.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.44% | 31.32% | -6.88% |
Volatility
FATE vs. IFRX - Volatility Comparison
Fate Therapeutics, Inc. (FATE) has a higher volatility of 28.84% compared to InflaRx N.V. (IFRX) at 25.77%. This indicates that FATE's price experiences larger fluctuations and is considered to be riskier than IFRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FATE | IFRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.84% | 25.77% | +3.07% |
Volatility (6M)Calculated over the trailing 6-month period | 73.19% | 66.92% | +6.27% |
Volatility (1Y)Calculated over the trailing 1-year period | 97.40% | 108.03% | -10.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.13% | 109.26% | -15.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.63% | 104.47% | -17.84% |
Dividends
FATE vs. IFRX - Dividend Comparison
Neither FATE nor IFRX has paid dividends to shareholders.
Financials
FATE vs. IFRX - Financials Comparison
This section allows you to compare key financial metrics between Fate Therapeutics, Inc. and InflaRx N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
FATE and IFRX have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FATE has higher volatility (28.84%) compared to IFRX (25.77%). In terms of maximum drawdown, FATE dropped -99.42% vs IFRX's -98.58%.
FATE currently has the higher Sharpe Ratio (1.73 vs 1.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FATE and IFRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer